Previous article Table of Contents  Next article

Year : 2023  |  Volume : 17  |  Issue : 2  |  Page : 301-302

Anesthetic management of patients with Morvan syndrome – A rare disorder

Department of Anesthesia and Critical Care, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

Correspondence Address:
Shelly Singh
Senior Resident, Department of Amesthesia and Critical Care, All India Institute of Medical Sciences, Jodhpur, Rajasthan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sja.sja_592_22

Rights and Permissions
Date of Submission15-Aug-2022
Date of Acceptance18-Aug-2022
Date of Web Publication10-Mar-2023

How to cite this article:
Singh S, Kumar R, Kumar S, Kaur M. Anesthetic management of patients with Morvan syndrome – A rare disorder. Saudi J Anaesth 2023;17:301-2

How to cite this URL:
Singh S, Kumar R, Kumar S, Kaur M. Anesthetic management of patients with Morvan syndrome – A rare disorder. Saudi J Anaesth [serial online] 2023 [cited 2023 Mar 30];17:301-2. Available from:

Dear Sir,

Morvan syndrome (MvS) is a rare constellation of neurological symptoms with peripheral nerve hyper-excitability, autonomic instability, and encephalopathy. It is an auto-immune disease with antibodies against voltage-gated potassium channel complex (VGKC).[1] Here, we are describing our experience of successful anesthetic management of a patient with MvS scheduled for right upper limb debridement.

An 83-year-old male patient was scheduled for debridement because of cellulitis of the right upper limb. He was a known case of MvS with fronto-temporal dementia with a right middle cerebral artery (MCA) infarct with left-sided hemiparesis.

Pre-operatively, the patient was drowsy and irritable, with a Glasgow coma scale (GCS) of 11 (E3V3M5). He was taking IV diltiazem 30 mg three times a day for rate control because of atrial fibrillation, and tablet dabigatran 110 mg for MCA infarction. Transthoracic echocardiography (TTE) revealed a 60% left ventricular ejection fraction (LVEF) with grade 3 diastolic dysfunction.

All standard ASA monitors were attached to the patient in the operating room, emergency cardiac drugs were arranged, and defibrillator pads were placed on the patient's chest. The patient was sedated with fentanyl and etomidate, and after achieving the desired level of anesthesia, a size 4 gel was inserted. Air, oxygen, and sevoflurane were used to maintain anesthesia. The procedure lasted 70 minutes and was uneventful. Post-operative analgesia was given in the form of paracetamol 1 gm intravenously thrice a day.

MvS is a rare neuromyotonia disorder that was first described in 1890 by Augustine Marie Morvan.[2],[3] It is distinguished by hyper-activity of the central, autonomic, and peripheral nervous systems. The etiology is either auto-immune or the result of a para-neoplastic syndrome. Patients with auto-immune etiology are more commonly associated with thymoma and have very good clinical responses to immuno-therapy.[4],[2]

There is a scarcity of literature on the safe administration of anesthesia in a patient with MvS, with only two case reports published to date depicting its anesthetic management. The most common intra-operative concerns are spontaneous laryngeal spasms caused by neuromyotonia and hyper-excitability caused by potassium channel abnormalities. As many of these patients are usually associated with thymoma, auto-antibodies against the acetylcholine receptor (AChR) can cause variable responsiveness to non-depolarizing neuro-muscular blockade. Thus, we decided to avoid muscle relaxants in our patient. Brachial plexus nerve block could be the procedure of choice if the patient was not on an oral anti-coagulant.

Thus, we can conclude that with vigilance, a multi-disciplinary approach, and thoughtful pharmacologic administration, the anesthesiologist can minimize intra-operative risks in MvS while facilitating safe surgical practice.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol 2012;72:241-55.  Back to cited text no. 1
Lee EK, Maselli RA, Ellis WG, Agius MA. Morvan's fibrillary chorea: A paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry 1998;65:857-62.  Back to cited text no. 2
Tufail S, Stacey M. General anaesthesia in a patient with Morvan's syndrome. Anaest Case 2013;1:97-9.  Back to cited text no. 3
Josephs KA, Silber MH, Fealey RD, Nippoldt TB, Auger RG, Vernino S. Neurophysiologic studies in Morvan syndrome. J Clin Neurophysiol 2004;21:440-5.  Back to cited text no. 4


Previous article    Next article
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  IN THIS Article

 Article Access Statistics
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal